Development and Validation of a Grading System for the Quality of Cost-Effectiveness Studies

Purpose.To provide a practical quantitative tool for appraising the quality of cost-effectiveness (CE) studies. Methods.A committee comprised of health economists selected a set of criteria for the instrument from an item pool. Data collected with a conjoint analysis survey on 120 international health economists were used to estimate weights for each criterion with a random effects regression model. To validate the grading system, a survey was sent to 60 individuals with health economics expertise. Participants first rated the quality of three CE studies on a visual analogue scale, and then evaluated each study using the grading system. Spearman rho and Wilcoxon tests were used to detect convergent validity and analysis of covariance (ANCOVA) for discriminant validity. Agreement between the global rating by experts and the grading system was also examined. Results.Sixteen criteria were selected. Their coefficient estimates ranged from 1.2 to 8.9, with a sum of 93.5 on a 100-point scale. The only insignificant criterion was “use of subgroup analyses.” Both convergent validity and discriminant validity of the grading system were shown by the results of the Spearman rho (correlation coefficient = 0.78, P <0.0001), Wilcoxon test (P = 0.53), and ANCOVA (F3,146 = 5.97, P = 0.001). The grading system had good agreement with global rating by experts. Conclusions. The instrument appears to be simple, internally consistent, and valid for measuring the perceived quality of CE studies. Applicability for use in clinical and resource allocation decision-making deserves further study.

[1]  A. Beckett,et al.  AKUFO AND IBARAPA. , 1965, Lancet.

[2]  J. Gray,et al.  The NHS economic evaluation database , 1997 .

[3]  W. R. Taylor,et al.  Health Care CBA/CEA: An Update on the Growth and Composition of the Literature , 1993, Medical care.

[4]  S. Hill,et al.  Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. , 2000, JAMA.

[5]  R B Haynes,et al.  Guidelines for the clinical and economic evaluation of health care technologies. , 1986, Social science & medicine.

[6]  K. Gerard Cost-utility in practice: a policy maker's guide to the state of the art. , 1992, Health policy.

[7]  M. Weinstein,et al.  Methods of cost-effectiveness analysis in the assessment of new drugs for Alzheimer's disease. , 1997, Psychiatric services.

[8]  W. McNee RE: M Thomas. The change of cost: reference-based pricing and the statins. 1999;15:535-8. , 1999, The Canadian journal of cardiology.

[9]  C. Mullins,et al.  Emerging standardization in pharmacoeconomics. , 1998, Clinical therapeutics.

[10]  M. Weinstein,et al.  Recommendations of the Panel on Cost-effectiveness in Health and Medicine. , 1996, JAMA.

[11]  A. Detsky,et al.  Canadian guidelines for economic evaluation of pharmaceuticals. Canadian Collaborative Workshop for Pharmacoeconomics. , 1996, PharmacoEconomics.

[12]  J. Sacristán,et al.  Evaluation of Pharmacoeconomic Studies: Utilization of a Checklist , 1993, The Annals of pharmacotherapy.

[13]  D. Menon,et al.  Use of economic evaluation guidelines: 2 years' experience in Canada. , 1998, Health economics.

[14]  M. Ryan,et al.  The use of conjoint analysis to elicit community preferences in public health research: a case study of hospital services in South Australia , 2000, Australian and New Zealand journal of public health.

[15]  C. Bell,et al.  The Quality of Reporting in Published Cost-Utility Analyses, 19761997 , 2000, Annals of Internal Medicine.

[16]  M. Thomas The change of cost: reference-based pricing and the statins. , 1999, The Canadian journal of cardiology.

[17]  T O Jefferson,et al.  Guidelines for authors and peer reviewers of economic submissions to the BMJ , 1996, BMJ.

[18]  G. Guyatt,et al.  Users' guides to the medical literature. , 1993, JAMA.

[19]  M. Drummond,et al.  The U.K. NHS ECONOMIC EVALUATION DATABASE , 2000, International Journal of Technology Assessment in Health Care.

[20]  G A Colditz,et al.  Cost-Effectiveness and Cost-Benefit Analyses in the Medical Literature , 1992, Annals of Internal Medicine.

[21]  L. Sanchez Evaluating the quality of published pharmacoeconomic evaluations. , 1995, Hospital pharmacy.

[22]  D Menon,et al.  Canada's new guidelines for the economic evaluation of pharmaceuticals. , 1996, Medical care.

[23]  B. Squires Methods for the Economic Evaluation of Health Care Programmes. , 1987 .

[24]  Thomas C. Chalmers,et al.  Economic Analysis in Randomized Control Trials , 1992, Medical care.

[25]  M. Drummond,et al.  Health Care Technology: Effectiveness, Efficiency and Public Policy@@@Methods for the Economic Evaluation of Health Care Programmes , 1988 .

[26]  J. Seymour,et al.  A TOOL TO IMPROVE QUALITY OF REPORTING PUBLISHED ECONOMIC ANALYSES , 2000, International Journal of Technology Assessment in Health Care.

[27]  A S Detsky,et al.  Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada. , 1993, PharmacoEconomics.

[28]  M F Drummond,et al.  Users' Guides to the Medical Literature: XIII. How to Use an Article on Economic Analysis of Clinical Practice A. Are the Results of the Study Valid? , 1997 .

[29]  D G Altman,et al.  Comparing two methods of clinical measurement: a personal history. , 1995, International journal of epidemiology.

[30]  J. Ratcliffe,et al.  PATIENTS' PREFERENCES REGARDING THE PROCESS AND OUTCOMES OF LIFE-SAVING TECHNOLOGY , 1999, International Journal of Technology Assessment in Health Care.

[31]  A. L. Hillman,et al.  Economic Analysis of Health Care Technology: A Report on Principles , 1995, Annals of Internal Medicine.

[32]  D. Altman,et al.  STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.